: Provide new therapies using stem cell technologies to patients suffering from diseases without treatment
Massage from CEO
I’m a Neurologist with more than 10-year experience. I helped many patients but there were still many patients suffering from neurological disorders with no treatments.
I worked at Kyoto University to develop gene therapies for these patients. But I felt a limitation of gene therapies at that time.
Then, I decided to go to NIH to learn stem cell technologies. After 5 years, I established a bio-venture company, Stem Cell Medicine, LLC in US to develop a novel cell therapy product.
In 2011, I discovered a new type of human neural stem cells that can differentiate into oligodendrocyte efficiently and named it “OligoGenie”.
After its patent was granted in Japan and a new regulation was introduced in Novermber, 2014, I came back to Japan and establiced Oligogen, Inc. to initiate a clinical trial for Pelizaeus-Merzbacher disease and spinal cord injury.
We have gotten Series-A investments from 4 VCs in August, 2017 and moved into Innovation Hub Kyoto in 2018.
To provide "OligoGenie" for patients with neurological disorders, such as Spinal cord injuries, Pelizaeus-Merzbacher disease (PMD), Multiple sclerosis, Alzheimer disease, etc., we are conducting a research and development of cell therapy products and drug screening for those diseases.
Tsuneo Kido, President & CEO